Melanocyte Stimulating Hormone Receptor- Pipeline Review, H2 2018 | Pharma Clinical Trial | ResearchByMarkets

September 22, 2018/Press Release/ResearchByMarkets/— Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Pipeline Review, H2 2018

Overview

According to the recently published report ‘Melanocyte Stimulating Hormone Receptor- Pipeline Review, H2 2018’; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 10 molecules. 

“Melanocyte Stimulating Hormone Receptor” (Melanocortin Receptor 1 or MSHR or MC1R) – Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin. 

The report ‘Melanocyte Stimulating Hormone Receptor- Pipeline Review, H2 2018’ outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 6 respectively. Report covers products from therapy areas Dermatology, Central Nervous System, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders, Genito Urinary System And Sex Hormones and Oncology which include indications Vitiligo, Amyotrophic Lateral Sclerosis, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease, Metastatic Melanoma, Multiple Sclerosis, Ocular Inflammation, Peritonitis, Porphyria (Erythropoietic Protoporphyri), Psoriatic Arthritis, Ulcerative Colitis and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/34700

Report Purview

– The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
– The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
– The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects 
– The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
– The report summarizes all the dormant and discontinued pipeline projects 
– The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Why buy this report?

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
– Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies 
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape 
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Buy this report via Credit Card/Paypal or Wire Transfer:
https://www.researchbymarkets.com/paynow/34700

Companies Mentioned: 
Clinuvel Pharmaceuticals Ltd
MallInckrodt Plc
Palatin Technologies Inc
SolaranRx Inc
SynAct Pharma AB

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.